BETNOVATE SCALP APPLICATION 0.1% ww

Kraj: Singapur

Język: angielski

Źródło: HSA (Health Sciences Authority)

Składnik aktywny:

BETAMETHASONE VALERATE EQV BETAMETHASONE

Dostępny od:

GLAXOSMITHKLINE PTE LTD

Kod ATC:

D07AC01

Dawkowanie:

0.1% w/w

Forma farmaceutyczna:

SOLUTION

Skład:

BETAMETHASONE VALERATE EQV BETAMETHASONE 0.1% w/w

Droga podania:

TOPICAL

Typ recepty:

Prescription Only

Wyprodukowano przez:

ASPEN BAD OLDESLOE GMBH

Status autoryzacji:

ACTIVE

Data autoryzacji:

1994-05-05

Ulotka dla pacjenta

CONFIDENTIAL 

BETNOVATE
TM
 SCALP APPLICATION 

PRESENTATION  
_BETNOVATE  _Scalp Application
is a transparent, slightly gelled solution containing 0.1% 
w/w betamethasone as valerate. The
vehicle contains 50% of isopropyl alcohol, which has 
antibacterial activity. This preparation complies with
the specifications for Betamethasone 
Valerate Scalp Application BP. 

CLINICAL INFORMATION 

INDICATIONS

Steroid responsive dermatoses of the scalp such as
psoriasis, seborrhoea capitis, 
inflammation associated with severe dandruff. 

DOSAGE AND ADMINISTRATION 

A small quantity of _BETNOVATE  _Scalp Application should
be applied to the scalp night 
and morning until improvement is noticeable. It may then
be possible to sustain 
improvement by applying once a day, or less frequently. 

Due to the flammable nature of betamethasone valerate
scalp application, patients should 
avoid smoking, heat including the use of hair dryer or being near an
open flame during 
application and immediately after use.  

CHILDREN 

Betamethasone valerate is contraindicated in children under one
year of age.  

Children are more likely to develop local and
systemic side effects of topical corticosteroids 
and, in general, require shorter courses and less
potent agents than adults.  

Care should be taken when
using betamethasone valerate to ensure the amount applied is 
the minimum that provides therapeutic benefit.  

ELDERLY  
The greater frequency of decreased hepatic or renal
function in the elderly may delay 
elimination if systemic absorption
occurs. Therefore the minimum quantity should be used 
for the shortest duration to achieve the desired clinical
benefit. 

RENAL / HEPATIC IMPAIRMENT 

In case of systemic absorption (when application is over a large
surface area for a

prolonged 
period) metabolism and elimination may be delayed
therefore i

Charakterystyka produktu

CONFIDENTIAL
BETNOVATE SCALP APPLICATION
PRESENTATION
_BETNOVATE _
Scalp Application is a transparent, slightly gelled solution
containing 0.1%
w/w betamethasone as valerate. The vehicle contains 50% of isopropyl
alcohol, which has
antibacterial activity. This preparation complies with the
specifications for Betamethasone
Valerate Scalp Application BP.
CLINICAL INFORMATION
INDICATIONS
Steroid responsive dermatoses of the scalp such as psoriasis,
seborrhoea capitis, inflammation
associated with severe dandruff.
DOSAGE AND ADMINISTRATION
A small quantity of
_BETNOVATE _
Scalp Application should be applied to the scalp night and
morning until improvement is noticeable. It may then be possible to
sustain improvement by
applying once a day, or less frequently.
Due to the flammable nature of betamethasone valerate scalp
application, patients should
avoid smoking, heat including the use of hair dryer or being near an
open flame during
application and immediately after use.
CHILDREN
Betamethasone valerate is contraindicated in children under one year
of age.
Children are more likely to develop local and systemic side effects of
topical corticosteroids
and, in general, require shorter courses and less potent agents than
adults.
Care should be taken when using betamethasone valerate to ensure the
amount applied is the
minimum that provides therapeutic benefit.
ELDERLY
The greater frequency of decreased hepatic or renal function in the
elderly may delay
elimination if systemic absorption occurs. Therefore the minimum
quantity should be used
for the shortest duration to achieve the desired clinical benefit.
RENAL / HEPATIC IMPAIRMENT
In case of systemic absorption (when application is over a large
surface area for a prolonged
period) metabolism and elimination may be delayed therefore increasing
the risk of systemic
toxicity. Therefore the minimum quantity should be used for the
shortest duration to achieve
the desired clinical benefit.
CONFIDENTIAL
CONTRAINDICATIONS
- Infections of the scalp.
- Hypersensitivitiy to any ingr